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REPLY
We appreciate the comments provided by Drs. Rundek and Spence
and recognize their important contribution to this area, docu-
mented by the cited references. We would, however, like to stress
that our data (1) were obtained in an asymptomatic population
without known cardiovascular disease, not only stroke-free as in the
Northern Manhattan Study (2), and neither “vascular patients” with
premature atherosclerosis or cerebrovascular disease as those stud-
ied by Dr. Spence (3). As previously reported (4), we agree that
ultrasonographic characteristics other than plaque size or plaque
burden may provide additional prognostic information, such as plaque
echolucency, heterogeneity, and surface irregularity and ulceration.We
also agree that the Tromsø study is important and did refer to it.
The High Risk Plaque BioImage study is the first large
population-based study with a cross-sectional evaluation of subclin-
ical arterial disease in 4 different arteries at the same baselinexamination (5), including quantitative assessment of carotid plaque
urden as described in our paper. We look forward to presenting
linical outcomes and their predictability by baseline findings in the
ear future.
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